In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...
Compared with DPP-4 inhibitor therapy, sustained GLP-1 receptor agonist (GLP-1 RA) therapy was associated with greater short‑ and long‑term improvements in A1c levels and a modest reduction in the ...
Depression risk lower with GLP-1 receptor agonists versus DPP-4 inhibitors in seniors, study reveals
For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared with dipeptidyl peptidase-4 ...
A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...
Dipeptidyl peptidase-4 (DPP4), also known as CD26, is a multifunctional serine protease expressed on numerous cell types and circulating in a soluble form. Beyond its established role in glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results